Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Abcuro, Inc logo — Developing immunotherapies for autoimmune diseases and cance...

Abcuro, Inc

Developing immunotherapies for autoimmune diseases and cancer

Founded 2015 43 employees Series B Total: $214.85M Biotechnology, Health Care +1

General Information

Company Name Abcuro, Inc
Founded Year 2015
Founders / Decision Makers
Team member
Employees 43
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Series B
Social

BounceWatch is an independent company data service, not affiliated with Abcuro, Inc. To contact Abcuro, Inc, visit abcuro.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Abcuro, Inc compare?

A PDF of Abcuro, Inc and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Abcuro, Inc soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Abcuro, Inc

Abcuro, Inc is a clinical stage biotechnology company founded in 2015 that focuses on developing immunotherapies for autoimmune diseases and cancer. The company is known for its flagship products ABC008 and ABC015, both of which target cytotoxic T and NK cells expressing the inhibitory immune checkpoint receptor KLRG1. ABC008, a first-in-class anti-KLRG1 antibody, aims to deplete cytotoxic T cells attacking healthy muscle tissue in patients with inclusion body myositis (IBM), a progressive and debilitating inflammatory skeletal muscle condition with no available pharmaceutical therapies. The noteworthy achievement is obtaining FDA orphan drug designation for ABC008 in IBM. On the other hand, ABC015, the company's anti-KLRG1 blocking antibody, is designed to reactivate inhibited cytotoxic T and NK cells in the tumor microenvironment. This holds significant promise in the realm of cancer treatment and underscores Abcuro's potential in addressing unmet medical needs. The most recent development for Abcuro, Inc is the $155.00M Series B investment which was secured on 17 August 2023. The investment involved notable backers such as Pontifax, RA Capital Management, BlackRock, Redmile Group, Samsara BioCapital, Sanofi Ventures, Soleus Capital, Mass General Brigham Ventures, Eurofarma, and Bain Capital Life Sciences. Abcuro's dedication to advancing treatments for autoimmune and cancer indications, coupled with its strategic partnerships and significant funding, positions the company as a compelling player in the biotechnology and healthcare industries.

Business keywords: Immunotherapy, Autoimmune diseases, Cancer treatments, Clinical stage, Anti-KLRG1 antibody, Orphan drug designation, Tumor microenvironment, Bioinformatics, Transcriptome analysis, Immune-modulatory bio-therapeutics, Target validation, Clinical insights, Cytotoxic T cells, NK cells

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Series B $155.00M 10
Pontifax RA Capital Management BlackRock
Pontifax, RA Capital Management +8
17 Aug 2023
Series A $42.00M -
07 Jan 2021
Venture Round $7.60M -
06 Jul 2020
Series A $8.00M -
09 Nov 2018
Seed Round $2.25M -
13 Dec 2016

Abcuro, Inc Alternatives & Competitors

View All Alternatives
Abcuro, Inc vs
ImmunOs Therapeutics AG
ImmunOs Therapeutics AG Switzerland

Novel human immunomodulatory proteins for cancer and autoimmune diseases with a specific role in inn...

Series B
15 employees
Biotechnology, Health Care
Compare Abcuro, Inc vs ImmunOs Therapeutics AG
Abcuro, Inc vs
Jounce Therapeutics, Inc.
Jounce Therapeutics, Inc. United States

Daring to create a world immune to cancer.

Post-IPO Equity
18 employees
Biotechnology, Health and Wellness
Compare Abcuro, Inc vs Jounce Therapeutics, Inc.
Abcuro, Inc vs
Surface Oncology Inc.
Surface Oncology Inc. United States

#lifeunderthesurface #BBJBestPlacesToWork2023,2022,2021 #BostonGlobeTopPlacesToWork2023,2022,2021

Post-IPO Equity
14 employees
Biotechnology, Health Care
View all alternatives

FAQ About Abcuro, Inc

Developing immunotherapies for autoimmune diseases and cancer
Abcuro, Inc was founded in 2015.
Abcuro, Inc operates in Biotechnology, Health Care and Health and Wellness. Its work centres on Immunotherapy, Autoimmune diseases, Cancer treatments and Clinical stage.
Abcuro, Inc has approximately 43 employees.
Abcuro, Inc has completed 5 funding rounds, raising a total of $214.85M. The latest funding stage is Series B.
Top alternatives and competitors to Abcuro, Inc include ImmunOs Therapeutics AG, Jounce Therapeutics, Inc., Surface Oncology Inc., ImCheck Therapeutics, Sensei Bio. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Abcuro, Inc and ImmunOs Therapeutics AG are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Abcuro, Inc, https://bouncewatch.com/company/abcuro-inc, updated 2 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout